Association of Mutation Location with Immune Tolerance Induction Outcomes in Children with Non-Inversion F8 Null Variants
Assoziation von Mutationslokalisation mit den Ergebnissen der Immuntoleranzinduktion bei Kindern mit Nicht-Inversions-F8-Nullvarianten
Thrombosis and Haemostasis · 04.11.2026
DOI: 10.1055/a-2994-8048 ↗Auf einen Blick
Bei 109 Kindern mit Hämophilie A war die Mutationslokalisation mit dem Erfolg der Immuntoleranzinduktion assoziiert. Schwerketten-Mutationen zeigten höhere Erfolgsraten als Leichtketten-Mutationen.
Fragestellung
Ist die genetische Lage von F8-Nullvarianten mit dem Erfolg der Immuntoleranzinduktion bei Kindern assoziiert?
Methode
Retrospektive Analyse von 109 Patient:innen mit Nullmutationen auf Ebene von Mutationstyp, -lokalisation sowie Domänen- und aa-Grenzen.
Ergebnisse
Gesamterfolg der ITI: 64,2 %. Nach multivariater Anpassung blieb die Mutationslokalisation assoziiert (OR 4,815; P = 0,013). Zeit bis 50 % Erfolg: 9,0 vs. 27,4 Monate (P = 0,013).
Einschränkungen
Explorative Analyse der aa-446-Grenze; externe Validierung erforderlich.
Schlussfolgerung der Autor:innen
Die Mutationslokalisation war mit der Heterogenität des ITI-Erfolgs assoziiert. Schwerketten-Mutationen hatten etwa 4,8-fach höhere Odds für ITI-Erfolg als Leichtketten-Mutationen.
Kernaussagen
- ITI-Gesamterfolg bei 109 Kindern: 64,2 %
- Schwerketten-Mutationen: OR 4,815 für ITI-Erfolg
- A1-Domäne als günstigste Zone; A3-C1 als Risikoregion
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Thrombosis and Haemostasis, erschienen am 04.11.2026. Verfasst von Zhengping Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Children's Hospital, Department of Hematology, Beijing, China, Beijing. Gefördert von: National Natural Science Foundation of China, Capital Health Research and Development of Special Fund.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Children with hemophilia A and F8 null mutations represent a refractory phenotype in immune tolerance induction (ITI). However, clinical heterogeneity remains poorly understood; thus, identifying driving factors is crucial for developing effective solutions.
Objective
To investigate the genetic factors underlying ITI outcome heterogeneity in pediatric F8 null mutations.
Methods
We retrospectively analyzed 109 patients with null mutations across three levels: (i) mutation type (nonsense, large deletions, frameshifts); (ii) mutation location (heavy- vs. light-chain); and (iii) specific domain and amino acid (aa) boundaries.
Results
The overall ITI success was 64.2%. Mutation location remained associated with ITI success after multivariable adjustment (odds ratio = 4.815, P = 0.013). Heavy-chain mutations demonstrated a significant advantage, with an estimated time to 50% success of 9.0 versus 27.4 months for light-chain mutations (P = 0.013). This location-dependent pattern was prominent in nonsense and large deletion but absent in frameshift mutations. Further refinement identified the A1-domain as the most favorable zone (highest success rate in nonsense subgroup: 100% [7/7]). In an exploratory analysis of nonsense mutations, mutations proximal to aa 446 showed higher observed success than those distal to it. Conversely, A3-C1 domains represented high-risk regions for failure.
Conclusions
Mutation location was associated with ITI outcome heterogeneity among patients with non-inversion F8 null variants. Heavy-chain mutations were associated with 4.8-fold higher odds of ITI success than light-chain mutations, mainly in nonsense mutations and large deletions. The A1-domain findings and exploratory aa 446 boundary may refine genetic risk stratification, but require external validation.
Autor:innen und Institutionen
- Beijing Children's Hospital, Department of Hematology, Beijing, China, Beijing.
- Beijing Children's Hospital Capital Medical University, Department of Hematology, --- Select One ---, China, Beijing.
- Beijing Children's Hospital Capital Medical University, Department of Hematology, Beijing, China, Beijing.
- Beijing Children's Hospital, Hematology, CHINA, China, Beijing.
- Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Department of Laboratory Medicine, Shanghai, China, Shanghai.
- Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Faculty of Medical Laboratory Science, China, Shanghai.
Förderung
- National Natural Science Foundation of China
- Capital Health Research and Development of Special Fund
Zitieren
APA
Li, Z., Zhang, J., Li, Z., Liu, G., Yao, W., Li, G., Cheng, X., Ai, D., Chen, Z., Wu, W., & Wu, R. (2026). Association of Mutation Location with Immune Tolerance Induction Outcomes in Children with Non-Inversion F8 Null Variants. Thrombosis and Haemostasis. https://doi.org/10.1055/a-2994-8048
Vancouver
Li Z, Zhang J, Li Z, Liu G, Yao W, Li G, et al. Association of Mutation Location with Immune Tolerance Induction Outcomes in Children with Non-Inversion F8 Null Variants. Thrombosis and Haemostasis. 2026. doi:10.1055/a-2994-8048
BibTeX
@article{Li2026,
author = {Li, Zhengping and Zhang, Jialu and Li, Zekun and Liu, Guoqing and Yao, Wanru and Li, Gang and Cheng, Xiaoling and Ai, di and Chen, Zhenping and Wu, Wenman and Wu, Runhui},
title = {Association of Mutation Location with Immune Tolerance Induction Outcomes in Children with Non-Inversion F8 Null Variants},
journal = {Thrombosis and Haemostasis},
year = {2026},
doi = {10.1055/a-2994-8048}
}
EUVIMED